Reduction in length of immunotherapy treatment for hard-to-treat melanoma shows promise in clinical trial

Reducing the length of immunotherapy treatment for an advanced skin cancer did not significantly diminish disease control when compared to giving treatments over a longer period, according to research led by the Universities of Sheffield and Leeds and Sheffield Teaching Hospitals NHS Foundation Trust.
đ Full Story

Chaos erupts at Family Dollar when Black cashier won't refund White woman's shirt #shorts
- The best power banks and portable chargers for every device in 2025 - Amy Skorheim
- A dangerous E. coli strain has emerged; a small mutation may explain its rise - Beth Mole
- Dark And Gritty Historical Horror On Max Is A Modern Cult Classic - Jonathan Klotz
- How and Where to Buy Dogecoin (DOGE)
- YRKKH Written Update 11 August 2024: Abhira Refuses to Marry Arman as Ruhiâs Plan Unfolds! - Aaradhana Chaurasia
- Bonfireâs new software lets users build their own social communities, free from platform control - Sarah Perez

Do Not Buy iPhones Right Now!
- Latent Technology raises $8M to change animation with generative physics - Dean Takahashi
- Taurine is unlikely to be a good aging biomarker, researchers find
- How to watch Appleâs WWDC 2025 keynote - Ivan Mehta
- Dots.eco is a platform for real-world environmental rewards in games - Dean Takahashi
- Just 1 in 4 Sunscreens Are Safe and Effective, Report ClaimsâDo Dermatologists Agree? - Simon Spichak
- Health Benefits of Serrapeptase - Ashley Wong, PharmD